The Society of Plastics Engineers (SPE) Extrusion Division will host the SPE Minitec-PLUS polyethylene terephthalate (PET)/polylactic acid (PLA) Extrusion, a two-day event at the Polymers Center in Charlotte, NC, on May 1–2, 2019.

CatSci has announced an expansion of its offering to include end-to-end services with an additional focus on lead optimization.

Big data technology company, Aigenpulse, has been granted with International Organization for Standardization (ISO) 9001:2015 and ISO 27001:2013 certification.

Sharp has invested US$650,000 into enhancing its Interactive Response Technology (IRT) solution.

Zogenix has submitted an NDA to the US Food and Drug Administration and an MAA to the European Medicines Agency for FINTEPLA.

Pathios Therapeutics and Sygnature Discovery have signed a strategic and innovative partnership agreement aimed at accelerating Pathios’ drug discovery and development programs.

The multi-year agreement will give Novartis access to AbCellera’s expertise and state-of-the-art antibody discovery technology for up to ten clinically-relevant disease targets.

The companies will use a $4.4-million grant from the National Institute of Allergy and Infectious Diseases to discover sustainable alternatives to shark squalene to use as vaccine adjuvants.

GS1, a global supply-chain standards organization, launched a new messaging standard in collaboration with GS1 US to help meet the requirements of the US Drug Supply Chain Security Act (DSCSA) for salable returns of serialized prescription drugs.

C-Bridge Capital will form a new biopharmaceutical company, AffaMed Therapeutics, which will collaborate with Samsung Bioepis to accelerate clinical development and registration of Samsung Bioepis’ next-generation biosimilars in China.

The strategic partnership is expected to bring a new source of supply to providers, alleviating in particular the two-year shortage of metoprolol injection.

Caron’s Wally CO2 incubators for laboratories are now available for purchase in the European Union.

The final part of the European Falsified Medicines Directive (EU FMD) is to come into force on Feb. 9, 2019, which means that all medicines within the European Union will need to comply with the safety features as laid out by the delegated regulation.

Nine award winners from the 2019 edition of Pharmapack Europe, covering innovations across drug delivery, packaging, and materials and components, have been announced by the event organizers.

The company will expand its global R&D footprint at its facility in Billerica, MA, with a $70-million investment.

The companies will jointly develop and commercialize an investigational bifunctional fusion protein immunotherapy currently in clinical development for cancer treatment.

PDA survey and conference discussion will generate information to guidance on technology transfer.

Mixing Dynamics has been selected as North American representative for Italvacuum dryers and pumps.

Supply chain players are eligible to participate in FDA’s pilot program to develop an electronic system for tracking drug products.

The companies will develop a software-connected pipetting system for improved reproducibility and traceability in life-science laboratories.

The US District Court for the Western District of Pennsylvania entered into a consent decree of permanent injunction against Ranier’s Rx Laboratory Inc., a compounding facility.

Researchers used magnesium particles as tiny motors to deliver an oral vaccine against the bacterial pathogen Staphylococcus aureus.

A study funded by the National Institutes of Health has created a virtual library expected to expand the availability of “make-on-demand” molecules for drug discovery.

Honeywell introduces Aclar Accel barrier film with faster production and delivery for pharma packaging.

The agency is requiring companies that make sartan blood pressure drugs to review their manufacturing processes due to the problem with impurities.

PCI Pharma Services expanded capacity of its commercial packaging site in Illinois.

The agency recommended six medicines for approval at its January 2019 meeting, including treatments for lung cancer, HIV-1, and autoimmune disorders.

The companies will develop Amprologix’s lead epidermicin-based antibiotic candidate.